Delayed inhalation therapy shifted apoptosis markers in late rat lung injury
A rat model of mixed-insult acute lung injury showed that delayed inhalation therapy could still alter the biology of late remodeling long after the initial insult. By day 21, placebo-treated animals had persistent respiratory dysfunction, fibrotic remodeling, and a marked pro-apoptotic shift in lung tissue, while inhaled camostat mesylate, methylprednisolone, and enoxaparin sodium each moved selected injury markers in a more favorable direction.
The design matters because the intervention did not begin at the moment of injury. Surviving animals received saline or one of the inhaled agents only from days 5 through 21, after systemic lipopolysaccharide priming and then a second pulmonary insult delivered through intratracheal capron/polyamide monofilament insertion and endotracheal lipopolysaccharide. In other words, treatment was tested in a delayed window, closer to the phase when uncontrolled cell death and matrix remodeling begin to lock in chronic damage rather than the early inflammatory burst alone.
A late pro-apoptotic shift dominated the untreated lungs
Untreated injured lungs showed a clear biochemical footprint of sustained cell death. Active caspase-3 rose 9.3-fold versus sham controls, Bax monomer increased 2.8-fold, and Bcl-xL fell 3.2-fold. Those changes fit a lung that is not simply inflamed, but trapped in a state where pro-apoptotic signaling outpaces the cell-survival machinery and normal alveolar repair cannot proceed cleanly.
This is the biological corridor that leads from acute damage to structural distortion. When caspase activation and Bax predominance persist, epithelial and endothelial loss can amplify barrier failure, distort repair, and leave behind a fibrotic scaffold rather than functional parenchyma. The histologic endpoint mirrored that biology: ATS-informed injury scoring based on H&E sections remained elevated in the placebo group, alongside respiratory impairment and fibrotic remodeling.
Each inhaled agent hit a different part of the apoptosis network
The three therapies did not behave identically, and the differences are clinically and mechanistically interesting. All of them reduced the proportion of caspase-3-immunopositive cells and partially normalized the apoptosis-related protein profile, but each agent appeared to favor a different node in the pathway.
Methylprednisolone produced the strongest reduction in Bax dimer. Camostat mesylate most strongly increased Bcl-xL. Enoxaparin sodium most strongly suppressed active caspase-3. Those pattern differences suggest that the delayed injury state is not governed by a single switch; it involves a network of apoptotic and survival signals that may respond differently to anti-inflammatory, anti-protease, and anticoagulant-biologic effects delivered directly to the lung.
The structural readout followed the same split pattern. Camostat and methylprednisolone significantly lowered histological injury scores, while enoxaparin produced a smaller reduction that did not reach statistical significance. One sentence captures the practical meaning: the lung did not respond to all inhaled therapies in the same way, even when the direction of change was broadly favorable.
Why apoptosis control may matter during fibrotic remodeling
Mixed-insult lung injury is not a single-hit problem. It combines systemic priming, direct airway damage, and ongoing inflammatory signaling, which can sustain epithelial loss well after the initiating event. If apoptosis remains excessive during this later phase, the lung is more likely to replace injured regions with disorganized repair, collagen deposition, and fixed loss of gas-exchange surface area.
That is why the balance between Bax, Bcl-xL, and caspase-3 matters. Bax promotes mitochondrial permeabilization and downstream cell death, Bcl-xL counteracts that process, and caspase-3 sits near the execution point of apoptosis. A therapy that shifts that trio toward survival could, at least in theory, preserve enough viable tissue architecture to blunt late remodeling rather than simply suppressing acute inflammation.
Inhaled delivery targeted the injury site after the initial insult
The route of administration is central to the interpretation. Inhalation places drug effect where the injury is happening, which is attractive in lung disease because it may concentrate biologic activity in the injured parenchyma while limiting systemic exposure. Here, delayed inhaled monotherapy still modified apoptosis-related proteins on day 21, after the model had already entered the remodeling phase.
That result supports the idea that late intervention may still be biologically relevant in established lung injury. It does not prove clinical benefit in people, and it does not identify the optimal timing, dose, or delivery schedule for each compound. The experiment did, however, show that the injured lung remains modifiable after the acute insult has passed, which is an important signal for a disease process often viewed as already irreversible once fibrosis begins to take hold.
The model raises translation questions before human use can be considered
The study was conducted in male Wistar rats, not in patients with ARDS or post-injury pulmonary fibrosis. The injury sequence also used a mixed systemic-pulmonary challenge rather than a conventional pulmonary-only model, and the investigators explicitly call for validation in standard pulmonary injury systems. Those boundaries are essential. A rat lung that improves histologically after delayed inhalation therapy is not the same thing as a critically ill human lung recovering from ventilator-associated or sepsis-related injury.
Still, the internal signal is coherent: delayed inhaled camostat mesylate, methylprednisolone, and enoxaparin sodium each reduced evidence of apoptosis, while two of the three therapies also lowered histologic injury scores. The strongest effects were not identical across agents, which argues against a one-size-fits-all mechanism and in favor of a pathway-specific approach to late lung repair.
No external funding supported the work, and the animal protocol was approved under institutional and regulatory oversight. What remains unresolved is whether the same apoptosis-linked remodeling axis can be safely and meaningfully targeted in humans once lung injury has moved beyond the initial inflammatory surge into the fibrotic phase.